CW Advisors LLC Takes $920,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• CW Advisors LLC purchased 1,428 shares of Regeneron Pharmaceuticals, valued at approximately $920,000, according to recent SEC filings.
• Several institutional investors significantly increased their stakes in Regeneron during the first quarter, including GAMMA Investing LLC, which raised its position by 89,825.0%.
• Regeneron reported $12.89 earnings per share for the most recent quarter, surpassing the expected $8.43, with revenues of $3.68 billion, reflecting a 3.6% increase year-over-year.

CW Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,428 shares of the biopharmaceutical company's stock, valued at approximately $920,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on REGN shares. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

REGN traded up $1.09 during trading on Friday, reaching $580.70. The stock had a trading volume of 574,305 shares, compared to its average volume of 1,042,369. The firm has a market capitalization of $61.55 billion, a price-to-earnings ratio of 14.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,210.97. The stock has a 50 day moving average of $557.26 and a two-hundred day moving average of $588.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.56 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.